Lung Cancer

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the phase II trial results using the marine-based drug lurbinectedin as a single agent treatment inpatients with small cell lung cancer.

China’s National Medical Products Administration has approved osimertinib for the frontline treatment of adult patients with locally-advanced or metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitutions.

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations.

Heather A. Wakelee, MD, medical oncologist, thoracic specialist, professor of medicine at Stanford University, discusses results from the phase III IMpower150 trial in non–small cell lung cancer.

Heather A. Wakelee, MD, professor of medicine, Stanford University Medical Center, discusses the rationale to explore osimertinib (Tagrisso) in combination with concurrent chemotherapy in patient with EGFR-mutant non–small cell lung cancer.

Lowell L. Hart, MD, FACP, scientific director of Clinical Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the impact of trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer.

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.

AbbVie has officially ended its rovalpituzumab tesirine (Rova-T) research and development program, which was exploring the antibody-drug conjugate in patients with small cell lung cancer.

Jüergen Wolf, MD, medical director, Center for Integrated Oncology, professor, Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses the primary efficacy data of the phase II GEOMETRY mono-1 trial exploring the MET inhibitor capmatinib as treatment for patients with non-small cell lung cancer and exon-14 mutations.

Edward B. Garon, MD, MS, highlights the 5-year KEYNOTE-001 data and also the activity with lurbinectedin in small cell lung cancer.

Practice-changing phase III trials including KEYNOTE-189, KEYNOTE-407, REVEL, and IMpower131, among several others, are laying the groundwork for how to treat patients with non–small cell lung cancer, specifically on an individualized basis.

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

A new drug application will be submitted to the FDA under accelerated approval status for lurbinectedin monotherapy for the second-line treatment of patients with small cell lung cancer, according to PharmaMar, the developer of the marine-derived agent.

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate of 41.7% in patients with relapsed small cell lung cancer.

The FDA has granted an accelerated approval to entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor a NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer.

Badi El-Osta, MD, discusses the targeted agents that are showing the most promise for patients with non–small cell lung cancer who have rare alterations and variants.